David Rizzieri, MD, Duke Health

Exploring Emerging Data in DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 23rd 2021

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Looking at the Big Picture in DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 23rd 2021

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

Treating Patients Post CAR T Therapy

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 23rd 2021

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Optimal Approaches to Bridging Therapy in DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 16th 2021

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

Evaluating CAR T Therapies in Lymphoma

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 16th 2021

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Recommendations for CAR T-Cell Therapy in R/R DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 9th 2021

Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.

Newer Approvals for Previously Treated DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 9th 2021

A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.

DLBCL: Approaches to Treating Patients Ineligible for Transplant

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 2nd 2021

Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.

Data From the L-MIND Trial

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 2nd 2021

Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).